Alexander J Lazar,Dennis P M Hughes,Shivaani Kummar
Department of Cancer Biology, The University of Texas MD Anderson Cancer Centeralazar@mdanderson.org.,Medical Oncology, National Cancer Institute.,Pediatrics, The University of Texas M.D. Anderson Cancer Center.
Publication
Summary
A phase I trial of PF-03084014, an oral reversible γ-secretase inhibitor (GSI), in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but often locally aggressive sarcoma.
Stay Up to Date as We Uncover More About Desmoid Tumors
